Dr. Bikash Ranjan Meher

Dr. Bikash Ranjan Meher

Addl. Prof.
Pharmacology

pharm_bikash@aiimsbhubaneswar.edu.in

Biosketch

30

PUBLICATIONS

0

CITATIONS

0

H INDEX

PERSONAL INFORMATION

Dr. Bikash Ranjan Meher

Addl. Prof.

Pharmacology

Degree / Diploma Name of the University/ Institution Subject Year of Passing
MBBS M.K.C.G. Medical College, Berhampur, Odisha
MD (Pharmacology) V.S.S. Medical College, Burla, Odisha
  • Pharmacoepidemiology
  • Clinical Trial and Evidence-based medicine
  • Diabetes and Metabolism,
  • Pharmacovigilance
  • Materiovigilance

  • Bonga KN, Agrawal K, Tripathy SK, Meher BR, Mishra A, Padhy BM. Effectiveness and safety of radionuclide synovectomy with Yttrium-90 hydroxyapatite in patients with inflammatory arthritis: a longitudinal study. Nucl Med Commun. 2025 Jan 29. Epub ahead of print. PMID: 39876797
  • Bonga KN, Mishra A, Maiti R, Padhy BM, Meher BR, Srinivasan A. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis. Obstet Gynecol. 2024 Mar 1;143(3):393-402. PMID: 38227939
  • Shukla S, Meher BR, Mishra A, Arora S, Kalaiselvan V, Raghuvanshi RS. Health-care Professionals’ Perception Toward Medical Device Postmarket Surveillance Practices: A Cross-sectional Study in India. Indian J Public Health. 2024 Jul 1;68(3):424-427. PMID: 39321232
  • Meher BR, Mishra A, Behera B, Ponnusamy S. Efficacy and Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Meta-Analysis. Cureus. 2024 Jul 13;16(7):e64488. PMID: 39139304
  • Meher BR, Mohanty RR, Dash A. Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor. Cureus. 2024 Feb 27;16(2): e55100. PMID: 38558672
  • Dash A, Meher BR, Padhy BM, Mohanty RR, Tripathy A. Comparison of Efficacy and Safety of Azilsartan and Amlodipine Combination Versus Telmisartan and Amlodipine Combination in Hypertensive Patients: A Non-Inferiority Trial. Cureus. 2023 Mar 7;15(3): e35865. PMID: 37033509
  • Meher BR, Dash A. Reporting of adverse events related to medical devices: A single-centre experience from a tertiary care institute of national importance in India. Indian J Pharmacol. 2023 Mar-Apr;55(2):128-132. PMID: 37313938
  • 8.Meher BR, Mohanty RR, Sahoo JP, Jena M, Srinivasan A, Padhy BM. Comparative Study of the Effects of Azilsartan and Telmisartan on Insulin Resistance and Metabolic Biomarkers in Essential Hypertension Associated with Type 2 Diabetes Mellitus. Cureus. 2022 Feb 16;14(2): e22301. PMID: 35350513
  • Meher BR, Mohanty RR. Identifying barriers to report adverse drug reactions using the Delphi method: Experience from an institute of national importance of India. Perspect Clin Res. 2022 Jan-Mar;13(1):58-59. PMID: 35198431
  • Mohanty RR, Biswa Mohan Padhy, Meher BR. Effectiveness of pulse dose methyl prednisolone in management of COVID 19: A systematic review and meta-analysis of observational studies. J Pharm Pharm Sci. 2022; 25:110-123. PMID: 35364003
  • Mohanty RR, Das S, Padhy BM, Meher BR. Comparison of Clinical Outcome between Dexamethasone and Methyl Prednisolone in Treatment of Moderate to Severe COVID-19: A Systematic Review and Meta-Analysis. J Assoc Physicians India. 2022 Jan;70(1):11-12. PMID: 35062806
  • Agrawal K, Padhy BM, Meher BR, Mohanty RR. Diagnostic utility of Ga-68 DOTA-SSTR and F-18 FDG PET/CT in the detection of culprit tumours causing osteomalacia: a systematic review and meta-analysis. Nucl Med Commun. 2021 Jun 1;42(6):646-655. PMID: 33625187
  • Meher BR, Mohanty RR, Padhy BM. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2021 Aug 13:1-9. PMID: 34315323
  • 14.Agrawal K, Patro PSS, Meher BR, Gnanasegaran G. Prevalence of Marine-Lenhart syndrome on 99mTc-thyroid scintigraphy and response to radioiodine: A single institutional retrospective study. World J Nucl Med. 2021 Sep 22;20(4):369-373 PMID: 35018152
  • Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2802-2807. PMID: 33829465
  • Meher BR. Need of Vibrant Vaccine Pharmacovigilance During Current Global COVID-19 Pandemic: More Than Ever. J Pharm Bioallied Sci. 2021 Jan-Mar;13(1):1-3 PMID: 34084042
  • Meher BR, Agrawal K, Gnanasegaran G. Review of Adverse Reactions Associated with the Use of Common Diagnostic Radiopharmaceuticals. Indian J Nucl Med. 2021 Apr-Jun;36(2):163-167, PMID: 34385787
  • Meher BR, Padhy BM. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings? Trop Doct. 2020 Apr;50(2):157-159. PMID: 32036770
  • Meher BR, Padhy BM, Das S, Mohanty RR, Agrawal K. Effectiveness of Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID 19 Patients: A Systematic Review and Meta-Analysis. J Assoc Physicians India. 2020 Dec;68(12):35-43. PMID: 33247641.
  • Meher BR, Srinivasan A, Vighnesh CS, Padhy BM, Mohanty RR. Factors most influencing antibiotic stewardship program and comparison of prefinal- and final-year undergraduate medical students. Perspect Clin Res. 2020 Jan-Mar;11(1):18-23. PMID: 32154145
  • Meher BR. Inclusion of Radiopharmaceuticals in the Indian Pharmacopeia: A Step Forward. Indian J Nucl Med. 2020 Jan-Mar;35(1):1-3. PMID: 31949360
  • Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020; 23:462-469 PMID: 33227231
  • Jena M, Ranjan R, Mishra BR, Mishra A, Nath S, Sahu P, Meher BR, Srinivasan A, Maiti R. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. J Psychiatr Res. 2019 May;112:1-6. doi: 10.1016/j.jpsychires.2019.02.007. Epub 2019 Feb 12. Erratum in: J Psychiatr Res. 2020 Jul; 126:141. PMID: 30782512
  • Meher BR. Vaccine pharmacovigilance in India: Current context and future perspective. Indian J Pharmacol. 2019 Jul-Aug;51(4):243-247. PMID: 31571710.
  • Meher BR, Agrawal K, Padhy BM. The Global Perspective of Pharmacovigilance in Nuclear Medicine Practice. Indian J Nucl Med. 2018 Oct-Dec;33(4):269-272. PMID: 30386045.
  • Padhy BM, Meher BR. Seeding trials: Marketing gimmick or credible scientific research. Indian J Anaesth. 2019 Mar;63(3):235-238. PMID: 30988540.
  • Agrawal K, Meher BR, Padhy BM. Ethical Conundrum in Nuclear Medicine Research in India. Indian J Nucl Med. 2019 Apr-Jun;34(2):83-85. PMID: 31040516; PMCID: PMC6481194
  • Meher BR, Balan S, Mohanty RR, Jena M, Das S. Biosimilars in India; Current Status and Future Perspectives. J Pharm Bioallied Sci. 2019 Jan-Mar;11(1):12-15. PMID: 30906134.
  • Meher BR. Materiovigilance: An Indian perspective. Perspect Clin Res. 2018 Oct-Dec;9(4):175-178. PMID: 30319948.
  • Raja IM, Basavareddy A, Mukherjee D, Meher BR. Randomized, double-blind, comparative study of oral metronidazole and tinidazole in treatment of bacterial vaginosis. Indian J Pharmacol. 2016 Nov-Dec;48(6):654-658. PMID: 28066102.

Dr. Bikash Ranjan Meher

Orcid ID
Scopus ID

Scopus ID
GS Image

Google Scholar ID
Researchgate ID

Researchgate ID
EXPERTISE INFORMATION
Areas of Interest
    • Pharmacoepidemiology
    • Clinical Trial and Evidence-based medicine
    • Diabetes and Metabolism,
    • Pharmacovigilance
    • Materiovigilance